Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Candidate Cancers for Vaccination Publisher



Keshavarzfathi M1, 2, 3 ; Rezaei N3, 4, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  3. 3. Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran

Source: Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives Published:2019


Abstract

Therapeutic cancer vaccines have been tested in a variety of tumors. Melanoma is one type of cancers that has received the most attention of researchers and clinicians who do research on immunotherapy. Melanoma has the highest mutation rate among various types of cancer and many tumor antigens associated with this malignancy have been identified. However, the most successful results with cancer vaccines have been achieved in patients with prostate cancer. Sipuleucel-T was the first cancer vaccine approved by the US Food and Drug Administration to treat hormone-refractory prostate cancer, which made it a prototype for cancer vaccine therapy. Here, we will review the characteristics of prostate cancer as well as the promising results of cancer vaccines for different types of cancer, including prostate, melanoma, lung, colorectal, and breast. © 2019 Nima Rezaei and Mahsa Keshavarz-Fathi Published by Elsevier Ltd. All rights reserved.
Related Docs
View other Related Docs
1. Candidate Cancers for Vaccination, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
2. Concluding Remarks and Future Perspectives on Therapeutic Cancer Vaccines, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
3. Concluding Remarks and Future Perspectives on Therapeutic Cancer Vaccines, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
4. Peptide and Protein Vaccines for Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
5. Peptide and Protein Vaccines for Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
6. Tumor Immunology, Clinical Immunology (2022)
7. Personalized Cancer Vaccine, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
8. Personalized Cancer Vaccine, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (16)
Forough Golsaz Shirazi (1)
Other Related Docs
9. Whole Tumor Cell Vaccine for Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
10. Immunotherapeutic Approaches for Cancer Therapy: An Updated Review, Artificial Cells# Nanomedicine and Biotechnology (2016)
11. Application of E75 Peptide Vaccine in Breast Cancer Patients: A Systematic Review and Meta-Analysis, European Journal of Pharmacology (2018)
12. Whole Tumor Cell Vaccine for Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
13. Mrna Cancer Vaccines From Bench to Bedside: A New Era in Cancer Immunotherapy, Biomarker Research (2024)
14. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
15. A Nano-Liposome Vaccine Carrying E75, a Her-2/Neu-Derived Peptide, Exhibits Significant Antitumour Activity in Mice, Journal of Drug Targeting (2018)
16. Combining Anti-Checkpoint Immunotherapies and Cancer Vaccines As a Novel Strategy in Oncological Therapy: A Review, Human Immunology (2025)
17. Toll-Like Receptors (Tlrs) in Cancer; With an Extensive Focus on Tlr Agonists and Antagonists, IUBMB Life (2021)
18. Cancer Immunology, Encyclopedia of Infection and Immunity (2022)
19. Cancer Immunoprevention: Current Status and Future Directions, Archivum Immunologiae et Therapiae Experimentalis (2021)
20. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
21. Immunology of Cutaneous Tumors and Immunotherapy for Melanoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)
22. Obstacles in the Development of Therapeutic Cancer Vaccines, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
23. Potent Anti-Tumor Immune Response and Tumor Growth Inhibition Induced by Her2 Subdomain Fusion Protein in a Mouse Tumor Model, Journal of Cancer Research and Clinical Oncology (2023)
24. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)
25. Obstacles in the Development of Therapeutic Cancer Vaccines, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
26. Development of Neoantigens: From Identification in Cancer Cells to Application in Cancer Vaccines, Expert Review of Vaccines (2022)